

Vitamin D replacement to prevent Acute Lung injury following Oesophagectomy (VINDALOO-2)

Submission date 03/11/2011	Recruitment status No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
Registration date 21/12/2011	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 29/10/2018	Condition category Cancer	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr David Thickett

Contact details

University of Birmingham
Birmingham
United Kingdom
B15 2TT
+44 (0)121 472 1311 (ext: 8289)
d.thickett@bham.ac.uk

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

version 1 3-3-2011

Study information

Scientific Title

Vitamin D replacement to prevent acute lung injury following oesophagectomy - a randomised placebo controlled trial

Acronym

VINDALOO-2

Study objectives

This is a randomised double-blind placebo-controlled study to test the safety and efficacy of rapid vitamin D replacement upon extravascular lung water and markers of alveolar/systemic inflammation in patients undergoing oesophagectomy.

The pilot study was registered in September 2011: www.controlled-trials.com/ISRCTN66719785

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised placebo-controlled phase II study

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied

Oesophageal cancer, acute lung injury

Interventions

Oral vitamin D liquid (100,000 IU) versus identical placebo

Intervention Type

Supplement

Primary outcome measure

Extravascular lung water index (EVLWI) at the end of oesophagectomy

Secondary outcome measures

Clinical markers indicative of lung injury:

1. P:F ratio
2. Oxygenation index
3. Development of lung injury / ARDS day 0-28
4. Duration of ventilation and organ failure, survival
5. Safety and tolerability of vitamin D supplementation
6. Plasma indices of endothelial and alveolar epithelial function/ injury
7. Plasma inflammatory response
8. Plasma LL-37 levels
9. Plasma vitamin D status (25D3, 1,25D3 and VDBP)
10. EVLWI post-operative day 1

Overall study start date

01/04/2012

Completion date

01/04/2014

Eligibility**Key inclusion criteria**

1. Planned transthoracic oesophagectomy for oesophageal carcinoma at a participating centre
2. Aged over 18 years on day of first dose of investigational medicinal product (IMP)
3. Ability to give written informed consent to participate in the study

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Both

Target number of participants

80

Key exclusion criteria

1. Known intolerance of vitamin D
2. Known sarcoidosis, hyperparathyroidism, or nephrolithiasis
3. Taking more than 1000iu/day vitamin D supplementation in the month preceding enrolment
4. Baseline serum corrected calcium >2.65 mmol/L
5. Undergoing haemodialysis

6. Pregnant or breastfeeding
7. Taking cardiac glycoside, carbamazepine, phenobarbital, phenytoin, primidone or long-term immunosuppressant therapy
8. Taking oral preparation containing > 10 micrograms vitamin D/day up to 2 months before first dose of IMP
9. Diagnosis of COPD with an FEV1 less than 50% predicted or resting oxygen saturations of less 92%

Date of first enrolment

01/04/2012

Date of final enrolment

01/04/2014

Locations

Countries of recruitment

England

United Kingdom

Study participating centre

University of Birmingham

Birmingham

United Kingdom

B15 2TT

Sponsor information

Organisation

University of Birmingham (UK)

Sponsor details

Edgbaston

Birmingham

England

United Kingdom

B15 2TT

+44 (0)121 414 3344

b.a.laverty@bham.ac.uk

Sponsor type

University/education

Website

<http://www.birmingham.ac.uk/>

ROR

<https://ror.org/03angcq70>

Funder(s)

Funder type

Research council

Funder Name

Medical Research Council UK (MRC) ref: G1100196

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Protocol article	protocol	17/04/2013		Yes	No
Results article	results	01/12/2018		Yes	No